BRAF Non-Small Cell Lung Cancer (BRAF+ NSCLC)
BRAF Non-Small Cell Lung Cancer (BRAF+ NSCLC) Market

BRAF mutated NSCLC is now a rare form of lung cancer. The biologic behaviour of BRAF mutated lung tumors tends to be more aggressive and resistant to chemotherapy. However, responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another useful tool to attain better response rates when compared to cytotoxic chemotherapy. The BRAF gene encodes for a serine/threonine kinase, which belongs to the RAS-RAF-MEK-ERK axis that regulates cellular growth.


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiological Segmentation 

The Epidemiological Segmentation of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of NSCLC patients
  • Total Incident Cases of NSCLC Patients by Histology
  • Total Diagnosed Cases of NSCLC Patients by Stages
  • Total Incident Cases of BRAF NSCLC
  • Treated Patient Pool of BRAF NSCLC 


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology 

  • BRAF NSCLC accounted for around 5% of the total cases of NSCLC
  • Total incident cases of BRAF mutated NSCLC in the 7MM in 2017 were 19,275  
  • The total cases of BRAF mutated NSCLC in the United States were 8,979 in 2017.


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market

The market size of BRAF mutated NSCLC in 7MM in 2017 was USD 273 million 


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Drivers

  • Increasing Use of Biomarker Testing 
  • Increase in the Mutation Specific Trials Activity
  • Increasing Incidence of BRAF mutated NSCLC

 

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Barriers

  • Cost-Effectiveness of Therapies
  • Small Patient Populations of BRAF mutated NSCLC
  • Cost of Therapies
  • Burden of Disease


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Emerging Drugs

The emerging drugs of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market are 

  • BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) 
  • ABM-1310 
  • LXH254 
  • Enfortumab Vedotin 

And many others. 


BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Key Players

The key players in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market are

  • Array BioPharma/ ONO Pharmaceuticals/ Pfizer
  • ABM Therapeutics
  • Novartis
  • Astellas Pharma/ Seattle Genetics

 And many others. 

Download Infographic